<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00246376</url>
  </required_header>
  <id_info>
    <org_study_id>H-14105</org_study_id>
    <secondary_id>R01HL073696</secondary_id>
    <nct_id>NCT00246376</nct_id>
  </id_info>
  <brief_title>Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia</brief_title>
  <acronym>HeartPositive</acronym>
  <official_title>Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Legacy Community Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of diet and exercise (DE), with and without niacin and
      fenofibrate, in reducing the cardiovascular risk of patients with HIV lipodystrophy or
      dyslipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      HIV lipodystrophy syndrome is associated with both metabolic (e.g., dyslipidemia and insulin
      resistance) and anthropomorphic (e.g., lipoatrophy and central obesity) abnormalities. These
      defects are likely to predispose HIV patients on highly active antiretroviral therapy (HAART)
      to accelerated cardiovascular morbidity. Based on studies of key mechanisms of altered lipid
      kinetics in these patients, evidence that DE patterns of patients with HIV lipodystrophy are
      inadequate to manage cardiovascular risk factors, and current recommendations for treatment
      of atherosclerosis and insulin resistance, the following is hypothesized: 1) an intensive
      lifestyle intervention with DE will improve the plasma lipid profile, decrease visceral fat
      mass, and improve hormonal, metabolic, and lipoprotein markers associated with insulin
      resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the
      intensive lifestyle intervention will result in further improvement in the cardiovascular
      risk profile.

      DESIGN NARRATIVE:

      This randomized, placebo-controlled study of 200 hypertriglyceridemic HIV patients on stable
      HAART treatment has the following specific aims: 1) to compare the effects of usual care,
      intensive DE, DE plus niacin, DE plus fenofibrate, and DE plus niacin plus fenofibrate on
      fasting plasma lipid concentrations (primary endpoint); 2) to compare the effects of the five
      treatment protocols on body fat distribution; and 3) to compare the effects of the five
      treatment protocols on hormonal, lipoprotein, and metabolic markers of insulin resistance.
      The collaborative team has expertise in lipid and lipoprotein metabolism, innovative and
      effective diet modification programs, intensive exercise programs in HIV patients, and
      studies of antilipidemic and antiretroviral agents. Therefore, this study will determine the
      efficacy of DE, with and without niacin and fenofibrate, in reducing the cardiovascular risk
      of patients with HIV lipodystrophy or dyslipidemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Measured at 24 weeks</time_frame>
    <description>Triglycerides (mg/dL): Fasting lipid levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-HDL-C</measure>
    <time_frame>Measured at 24 weeks</time_frame>
    <description>non-HDL-C (mg/dL): Fasting lipid levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL-C</measure>
    <time_frame>Measured at 24 weeks</time_frame>
    <description>HDL-C (mg/dL): Fasting lipid levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Measured at 24 weeks</time_frame>
    <description>Total cholesterol (mg/dL): Fasting lipid levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol : HDL-C Ratio</measure>
    <time_frame>Measured at 24 weeks</time_frame>
    <description>Total cholesterol : HDL-C ratio: Fasting lipid levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>Measured at 24 weeks</time_frame>
    <description>Adiponectin (micrograms/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition</measure>
    <time_frame>Measured at 24 weeks</time_frame>
    <description>Body cell mass (kg)
Fat mass (kg)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>HIV Infections</condition>
  <condition>Hyperlipidemia</condition>
  <condition>Hypertriglyceridemia</condition>
  <condition>Insulin Resistance</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive lifestyle advice and placebos for Niaspan and Tricor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet, exercise, and two placebos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet, exercise, Niaspan, and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet, exercise, placebo, and Tricor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet, exercise, Niaspan, and Tricor</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>ATP-III diet</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Supervised exercise in study gym</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin</intervention_name>
    <description>Niaspan, titrated up to 2 grams per day</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Tricor, 120 mg per day</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos for Niaspan and Tricor</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive

          -  On stable HAART regimen for at least 6 months prior to study entry

          -  T-cell count greater than 100 and viral load less than 1,000 for at least 6 months
             prior to study entry

          -  Fasting triglyceride level greater than 150 mg/dl

          -  Body mass index (BMI) greater than 18.5 and less than 30

          -  Uses barrier contraception

        Exclusion Criteria:

          -  Fasting triglyceride level greater than 1000 mg/dl

          -  BMI less than 18.5 or greater than 30

          -  Taking diabetic medication or HbA1c less than 7.0

          -  Use of lipid lowering medication in the 30 days prior to study entry

          -  Unable to exercise

          -  T-cell count less than 100

          -  Current medical condition that makes exercise unadvisable

          -  History of coronary artery disease (CAD)

          -  Use of dietary supplements (within 30 days of study entry) that may affect lipid
             levels including, but not limited to, the following:

               1. Omega-3 fatty acids

               2. L-Carnitine

               3. Soluble fiber supplements

               4. Guggul

               5. Garlic supplements

               6. Niacin greater than 25mg/d

               7. Oral liquid supplements

          -  Use of steroids, hormones, or testosterone (without diagnosis of hypogonadism,
             testosterone less than 300 ng/dl)

          -  Irregular periods

          -  Depo-Provera

          -  Hypo- or Hyperthyroidism

          -  Adrenal insufficiency

          -  Serum alanine or aspartate aminotransferase level greater than 3 times the upper limit
             of normal

          -  Alcohol abuse

          -  Renal insufficiency (creatinine level greater than 1.5 mg/dl)

          -  Coumadin therapy

          -  Pregnancy

          -  Peptic ulcer disease

          -  Cholelithiasis

          -  History of hyperuricemia

          -  History of myositis or rhabdomyolysis

          -  Known adverse reaction to niacin or fibrates

          -  Hepatitis C therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashok Balasubramanyam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Samson SL, Pownall HJ, Scott LW, Ballantyne CM, Smith EO, Sekhar RV, Balasubramanyam A. Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials. 2006 Dec;27(6):518-30. Epub 2006 Jul 21.</citation>
    <PMID>16914390</PMID>
  </reference>
  <results_reference>
    <citation>Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, Iyer D, Taylor AA, Giordano TP, Sekhar RV, Clark P, Cuevas-Sanchez E, Kamble S, Ballantyne CM, Pownall HJ. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of &quot;heart positive,&quot; a randomized, controlled trial. J Clin Endocrinol Metab. 2011 Jul;96(7):2236-47. doi: 10.1210/jc.2010-3067. Epub 2011 May 11.</citation>
    <PMID>21565796</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2005</study_first_submitted>
  <study_first_submitted_qc>October 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2005</study_first_posted>
  <results_first_submitted>October 20, 2015</results_first_submitted>
  <results_first_submitted_qc>February 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 21, 2016</results_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Ashok Balasubramanyam</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited mainly from the Legacy Community Health Center and Thomas Street Clinic of the Harris County Hospital District and from Houston Area Community Services and private clinics. Recruitment period: January 2004 to September 2009.</recruitment_details>
      <pre_assignment_details>If potential subjects were taking nutritional supplements or lipid-lowering drugs, these were discontinued for washout for 6 weeks - baseline fasting lipid levels were then measured to determine eligibility prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Usual Care</title>
          <description>Subjects receive lifestyle advice and placebos for Niaspan and Tricor</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Diet / Exercise</title>
          <description>Diet, exercise, and two placebos</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Diet / Exercise + Fenofibrate</title>
          <description>Diet, exercise, Fenofibrate, and Niaspan placebo</description>
        </group>
        <group group_id="P4">
          <title>Group 4: Diet / Exercise + Niacin</title>
          <description>Diet, exercise, Fenofibrate placebo, and Niaspan</description>
        </group>
        <group group_id="P5">
          <title>Group 5: Diet / Exercise + Niacin + Fenofibrate</title>
          <description>Diet, exercise, Fenofibrate and Niaspan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>After Dietary run-in at Two Weeks</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Dropped/withdrew during dietary run-in</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Usual Care</title>
          <description>Subjects receive lifestyle advice and placebos for Niaspan and Tricor</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Diet / Exercise</title>
          <description>Diet, exercise, and two placebos</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Diet / Exercise + Fenofibrate</title>
          <description>Diet, exercise, Fenofibrate, and Niaspan placebo</description>
        </group>
        <group group_id="B4">
          <title>Group 4: Diet / Exercise + Niacin</title>
          <description>Diet, exercise, Fenofibrate placebo, and Niaspan</description>
        </group>
        <group group_id="B5">
          <title>Group 5: Diet / Exercise + Niacin + Fenofibrate</title>
          <description>Diet, exercise, Fenofibrate and Niaspan</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="47"/>
            <count group_id="B5" value="45"/>
            <count group_id="B6" value="221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Triglycerides</title>
        <description>Triglycerides (mg/dL): Fasting lipid levels</description>
        <time_frame>Measured at 24 weeks</time_frame>
        <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Usual Care</title>
            <description>These subjects did not participate in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Diet/Exercise Only</title>
            <description>These subjects participated in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Diet/Exercise + Fenofibrate</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + niacin placebo.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Diet/Exercise + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active niacin + fenofibrate placebo.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Diet/Exercise + Fenofibrate + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + active niacin.</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>Triglycerides (mg/dL): Fasting lipid levels</description>
          <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" spread="24.9"/>
                    <measurement group_id="O2" value="216.9" spread="28.6"/>
                    <measurement group_id="O3" value="155.1" spread="18.5"/>
                    <measurement group_id="O4" value="177.6" spread="24.2"/>
                    <measurement group_id="O5" value="135.6" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>Adiponectin (micrograms/ml)</description>
        <time_frame>Measured at 24 weeks</time_frame>
        <population>All subjects who completed 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Usual Care</title>
          </group>
          <group group_id="O2">
            <title>Group 2 - Diet/Exercise Only</title>
          </group>
          <group group_id="O3">
            <title>Group 3 - Diet/Exercise + Fenofibrate</title>
          </group>
          <group group_id="O4">
            <title>Group 4 - Diet/Exercise + Niacin</title>
          </group>
          <group group_id="O5">
            <title>Group 5 - Diet/Exercise + Fenofibrate + Niacin</title>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Adiponectin (micrograms/ml)</description>
          <population>All subjects who completed 24 weeks.</population>
          <units>micrograms/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="2"/>
                    <measurement group_id="O2" value="6.7" spread="1.6"/>
                    <measurement group_id="O3" value="9.5" spread="1.6"/>
                    <measurement group_id="O4" value="11.9" spread="3"/>
                    <measurement group_id="O5" value="10.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA-IR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.47"/>
                    <measurement group_id="O2" value="1.38" spread="0.36"/>
                    <measurement group_id="O3" value="2.02" spread="0.47"/>
                    <measurement group_id="O4" value="2.76" spread="0.75"/>
                    <measurement group_id="O5" value="2.38" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin sensitvity index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="0.73"/>
                    <measurement group_id="O2" value="4.95" spread="1.1"/>
                    <measurement group_id="O3" value="3.81" spread="0.76"/>
                    <measurement group_id="O4" value="2.88" spread="0.67"/>
                    <measurement group_id="O5" value="2.38" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.12" spread="1.09"/>
                    <measurement group_id="O2" value="6.04" spread="0.98"/>
                    <measurement group_id="O3" value="5.24" spread="0.76"/>
                    <measurement group_id="O4" value="11.01" spread="1.87"/>
                    <measurement group_id="O5" value="10.34" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition</title>
        <description>Body cell mass (kg)
Fat mass (kg)</description>
        <time_frame>Measured at 24 weeks</time_frame>
        <population>The number corresponds to the number of subjects who completed the study (see Participant flow)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Usual Care</title>
          </group>
          <group group_id="O2">
            <title>Group 2 - Diet/Exercise</title>
          </group>
          <group group_id="O3">
            <title>Group 3 - Diet/Exercise + Fenofibrate</title>
          </group>
          <group group_id="O4">
            <title>Group 4 - Diet/Exercise + Niacin</title>
          </group>
          <group group_id="O5">
            <title>Group 5 - Diet/Exercise + Fenofibrate + Niacin</title>
          </group>
        </group_list>
        <measure>
          <title>Body Composition</title>
          <description>Body cell mass (kg)
Fat mass (kg)</description>
          <population>The number corresponds to the number of subjects who completed the study (see Participant flow)</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body cell mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="2.3"/>
                    <measurement group_id="O2" value="67.3" spread="2"/>
                    <measurement group_id="O3" value="66.6" spread="1.8"/>
                    <measurement group_id="O4" value="67.1" spread="2.1"/>
                    <measurement group_id="O5" value="68.2" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="1.9"/>
                    <measurement group_id="O2" value="37.5" spread="1.6"/>
                    <measurement group_id="O3" value="35.8" spread="1.5"/>
                    <measurement group_id="O4" value="37.7" spread="1.8"/>
                    <measurement group_id="O5" value="36.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-HDL-C</title>
        <description>non-HDL-C (mg/dL): Fasting lipid levels</description>
        <time_frame>Measured at 24 weeks</time_frame>
        <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Usual Care</title>
            <description>These subjects did not participate in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Diet/Exercise Only</title>
            <description>These subjects participated in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Diet/Exercise + Fenofibrate</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + niacin placebo.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Diet/Exercise + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active niacin + fenofibrate placebo.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Diet/Exercise + Fenofibrate + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + active niacin.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-HDL-C</title>
          <description>non-HDL-C (mg/dL): Fasting lipid levels</description>
          <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.2" spread="7.8"/>
                    <measurement group_id="O2" value="165.4" spread="8.1"/>
                    <measurement group_id="O3" value="145.8" spread="7.4"/>
                    <measurement group_id="O4" value="154" spread="8.3"/>
                    <measurement group_id="O5" value="137.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HDL-C</title>
        <description>HDL-C (mg/dL): Fasting lipid levels</description>
        <time_frame>Measured at 24 weeks</time_frame>
        <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Usual Care</title>
            <description>These subjects did not participate in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Diet/Exercise Only</title>
            <description>These subjects participated in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Diet/Exercise + Fenofibrate</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + niacin placebo.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Diet/Exercise + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active niacin + fenofibrate placebo.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Diet/Exercise + Fenofibrate + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + active niacin.</description>
          </group>
        </group_list>
        <measure>
          <title>HDL-C</title>
          <description>HDL-C (mg/dL): Fasting lipid levels</description>
          <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="1.8"/>
                    <measurement group_id="O2" value="38.7" spread="1.9"/>
                    <measurement group_id="O3" value="40.7" spread="1.8"/>
                    <measurement group_id="O4" value="41.8" spread="2.2"/>
                    <measurement group_id="O5" value="44.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Cholesterol</title>
        <description>Total cholesterol (mg/dL): Fasting lipid levels</description>
        <time_frame>Measured at 24 weeks</time_frame>
        <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Usual Care</title>
            <description>These subjects did not participate in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Diet/Exercise Only</title>
            <description>These subjects participated in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Diet/Exercise + Fenofibrate</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + niacin placebo.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Diet/Exercise + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active niacin + fenofibrate placebo.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Diet/Exercise + Fenofibrate + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + active niacin.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <description>Total cholesterol (mg/dL): Fasting lipid levels</description>
          <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.6" spread="7.7"/>
                    <measurement group_id="O2" value="200.1" spread="8.3"/>
                    <measurement group_id="O3" value="184" spread="6.9"/>
                    <measurement group_id="O4" value="190.8" spread="8.2"/>
                    <measurement group_id="O5" value="178.4" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Cholesterol : HDL-C Ratio</title>
        <description>Total cholesterol : HDL-C ratio: Fasting lipid levels</description>
        <time_frame>Measured at 24 weeks</time_frame>
        <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Usual Care</title>
            <description>These subjects did not participate in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Diet/Exercise Only</title>
            <description>These subjects participated in the diet/exercise program and took placebos.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Diet/Exercise + Fenofibrate</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + niacin placebo.</description>
          </group>
          <group group_id="O4">
            <title>Group 4 - Diet/Exercise + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active niacin + fenofibrate placebo.</description>
          </group>
          <group group_id="O5">
            <title>Group 5 - Diet/Exercise + Fenofibrate + Niacin</title>
            <description>These subjects participated in the diet/exercise program and took active fenofibrate + active niacin.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol : HDL-C Ratio</title>
          <description>Total cholesterol : HDL-C ratio: Fasting lipid levels</description>
          <population>All those who underwent the 2-week (first follow-up) measurement and continued in the study.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.3"/>
                    <measurement group_id="O2" value="5.1" spread="0.3"/>
                    <measurement group_id="O3" value="4.5" spread="0.2"/>
                    <measurement group_id="O4" value="4.6" spread="0.3"/>
                    <measurement group_id="O5" value="4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout duration of study (5 years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Usual Care</title>
          <description>Subjects receive lifestyle advice and placebos for Niaspan and Tricor</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Diet / Exercise</title>
          <description>Diet, exercise, and two placebos</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Diet / Exercise + Fenofibrate</title>
          <description>Diet, exercise, Fenofibrate, and Niaspan placebo</description>
        </group>
        <group group_id="E4">
          <title>Group 4: Diet / Exercise + Niacin</title>
          <description>Diet, exercise, Fenofibrate placebo, and Niaspan</description>
        </group>
        <group group_id="E5">
          <title>Group 5: Diet / Exercise + Niacin + Fenofibrate</title>
          <description>Diet, exercise, Fenofibrate and Niaspan</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain / angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminases elevated &gt;3 times upper normal limit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <description>Elevated Bilirubin</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Triglycerides &gt; 1000mg/dl</sub_title>
                <description>hypertriglyceridemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Serum creatining &gt; 1.5 mg/dL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Body ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/Itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>High dropout rate, especially by loss to follow-up (with no explanation). Flushing was common among patients taking niacin, and this (with transportation and socio-economc problems) could have contributed to the high drop-out rate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ashok Balasubramanyam, MD, Prinicipal Investigator</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-8654</phone>
      <email>ashokb@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

